James Karis, president and CEO of Entelos, said: “The deal reinforces Entelos’s stated strategy to enable proprietary drug development, particularly in chronic disease areas where multiple drugs, treatment choices, and large differences between patients make it difficult for health-care providers to select the best treatments.”